Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
NCT00411645 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
Conditions Studied
Interventions
- OTHER placebo
- DRUG maribavir
Study Locations (20)
California
- City of Hope Medical Center — Duarte
- Scripps Green Hospital — La Jolla
- UCSD Moores Center — La Jolla
- UCLA Medical Center — Los Angeles
- University of California, San Francisco — San Francisco
- Stanford University Medical Center — Stanford
Illinois
- Northwestern University Medical Center — Chicago
- University of Chicago — Chicago
- Loyola University — Maywood
Florida
- Shands Hospital — Gainesville
- H. Lee Moffitt Cancer Center — Tampa
Kentucky
- University of Kentucky Chandler Medical Center — Lexington
- University Medical Center University of Louisville Hospital — Louisville
Arkansas
- University of Arkansas Myeloma Institute — Little Rock
Colorado
- Rocky Mountain Cancer Center — Denver
Georgia
- Emory University — Atlanta
Indiana
- St Francis Hospital — Beech Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 681 participants |
| Start Date | 2006-12-13 |
| Est. Completion | 2009-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411645
The ClinicalTrials.gov registry entry for NCT00411645 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 681 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 56 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00411645 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00411645 about?
NCT00411645 is a clinical study titled "Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients". The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
What is the current status of trial NCT00411645?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 681 participants. The study started on 2006-12-13. Estimated completion is 2009-05-23.
What conditions does trial NCT00411645 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00411645?
The interventions under investigation include: placebo (OTHER), maribavir (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00411645?
This trial is sponsored by Shire, which has 56 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00411645 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.